Society for Translational Oncology Inc
Balance Sheet
Fiscal Year: 2024
Assets in 2024 (Year End)
$1,476,634
Investments
89%
Cash & Equivalents
9%
Prepaid Expenses
<1%
Receivables (Non-Related)
<1%
Other Assets
<1%
Related-Party Receivables
0%
Inventories
0%
Property, Plant, & Equipment (net)
0%
Liabilities in 2024 (Year End)
$65,042
Payables & Accruals
96%
Other Liabilities
4%
Grants Payable
0%
Deferred Revenue
0%
Tax-Exempt Bond Liabilities
0%
Custodial & Escrow Liabilities
0%
Notes Payable / Debt (Non-Related)
0%
Related-Party Payables
0%
Assets
2023
2024
Change
Cash & Equivalents
$275,220
$138,984
-50%
Receivables (Non-Related)
$107
$10,783
+9978%
Related-Party Receivables
-
-
-
Inventories
-
-
-
Prepaid Expenses
$14,078
$14,542
+3%
Investments
$1,235,777
$1,309,973
+6%
Property, Plant, & Equipment (net)
$815
$0
-100%
Other Assets
-
$2,352
-
Total Assets
$1,525,997
$1,476,634
-3%
Liabilities
2023
2024
Change
Payables & Accruals
$116,785
$62,449
-47%
Grants Payable
-
-
-
Deferred Revenue
-
-
-
Tax-Exempt Bond Liabilities
-
-
-
Custodial & Escrow Liabilities
-
-
-
Notes Payable / Debt (Non-Related)
-
-
-
Related-Party Payables
-
-
-
Other Liabilities
$2,040
$2,593
+27%
Total Liabilities
$118,825
$65,042
-45%
Net assets
2023
2024
Change
Restricted Net Assets
$1,002,291
$812,749
-19%
Unrestricted Net Assets
$404,881
$598,843
+48%
Net assets
2023
2024
Change
Net assets
+$1,407,172
+$1,411,592
+0%
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)